Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has closed a $74 million Series B round co-led by China’s State Development Investment Corporation (SDIC) Fund and Sherpa Healthcare Partners, it said in a statement on Wednesday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
